MoonLake Immunotherapeutics
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Other eventsSep 30 →Insiders1 insider bought $98,808 in 1 open-market buy. 13 insiders sold $77.8M, 10 of 19 sales on a 10b5-1 plan.→HoldersBVF Inc/il 21.7%Deep Track Capital 9.5%D. E. Shaw & 4.6%→PeersClosest companies: STTK, ROIV, APGE→
From the filings
Figures
- Net income
- −$263.7Mlast 12 months
- Operating cash flow
- −$224.2Mlast 12 months
- Cash and equivalents
- $477.9Mat the last balance sheet
- Total debt
- $99.5Mat the last balance sheet
- Shares outstanding
- 73.6M shareson issue